新股公告 | 先瑞達醫療-B(06669)8月12日-8月17日招股 中金公司參與認購
智通財經APP訊,先瑞達醫療-B(06669)8月12日-8月17日招股。公司發行6863.3萬股,其中90%爲國際發售,10%爲公開發售,另有最多15%超額配股權。每股發行價22.2-23.8港元。每手1000股。預期8月24日上市。
公司是一家創新醫療器械企業。2019年-2020年,公司收益爲人民幣1.25億元及1.9億元。研發開支爲人民幣2550萬元及8350萬元。
基石投資者匯添富、CPE Investment Wu、中金公司、Valliance Fund、Perseverance Asset
Management、達觀國際、Athos Capital、Panjing Fund、Dymon Asia、保銀、PRIMEONE LUCK
LIMITED、易方達基金及新裏程集團認購總金額1.05億美元可購買的有關數目的發售股份。
假設超額配股權未獲行使,所得款項淨額14.7億港元(以發行價中位數計算),32%撥作持續研發及商業化公司的核心產品;23%開發及商業化公司於現有產品管線的其餘產品;24%用於通過內部研發、合作、合併及收購、授權引進及╱或股權投資等方式擴大公司的產品組合;7%用於強化製造能力;8%撥作營運資金及一般企業用途;6%撥作償還該貸款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.